Cynthia Fernández-Lainez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cynthia Fernández-Lainez has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Isabel Ibarra-González
Unidad de Genética de la Nutrición, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), Mexico City 04510, Mexico
9 shared publications - Marcela Vela-Amieva
Laboratorio de Errores Innatos del Metabolismo y Tamiz, Instituto Nacional de Pediatría, Mexico City 04530, Mexico
9 shared publications - Susana Monroy-Santoyo
Laboratorio de Errores Innatos del Metabolismo y Tamiz, Instituto Nacional de Pediatría, Secretaría de Salud, México
6 shared publications - Leticia Belmont-Martínez
Instituto Nacional de Pediatría, Ciudad de México, México
3 shared publications - Sara Guillén-López
Laboratorio de Errores Innatos del Metabolismo y Tamiz, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City 04530, Mexico
2 shared publications A Hernández-Montiel
Laboratorio de Errores Innatos del Metabolismo y Tamiz, Instituto Nacional de Pediatría, Secretaríade Salud, México
1 shared publication
Latest Publications
- 16 August 2017
- Published by Wiley in Neuropathology
- Vol. 37 (6) , 586-590
Kernicterus in a boy with ornithine transcarbamylase deficiency: A case report
Ornithine transcarbamylase deficiency (OTCD) is an X‐linked urea cycle defect associated with severe and usually fatal hyperammonemia. This study describes a patient with early onset lethal OTCD due to a known pathogenic variant (c.298+1G>A), as well as the novel autopsy finding of kernicterus with relatively low blood concentration of unconjugated bilirubin (UCB) (11.55 mg/dL). The patient was a full‐term male with a family history of two previous male siblings who died as newborns after acute neurologic deterioration. The patient's symptoms began at 24 h of life with lethargy that rapidly progressed to coma upon admission to the neonatal intensive care unit. Although hyperammonemia and hyperbilirubinemia were documented, hemofiltration could not be performed. OTCD diagnosis was biochemically established. Despite nutritional intervention and treatment for hyperammonemia, the patient died on the sixth day of life. At autopsy, external brain examination revealed a marked yellow pigmentation typical of kernicterus that included gray matter, particularly the thalamus and basal ganglia; dentate nuclei of the cerebellum and brain stem gray matter were also affected. Microscopic findings were consistent with the classical description of tissue damage in OTCD, including the presence of Alzheimer type II astrocytes in basal ganglia, necrosis, neuronal loss with spongiform degeneration and macrophage infiltration surrounded by astroglia. This condition may be an important comorbidity in newborns with hyperammonemia.
- 16 August 2017
- Published by Wiley in Neuropathology
- Vol. 37 (6) , 586-590
Kernicterus in a boy with ornithine transcarbamylase deficiency: A case report
Ornithine transcarbamylase deficiency (OTCD) is an X‐linked urea cycle defect associated with severe and usually fatal hyperammonemia. This study describes a patient with early onset lethal OTCD due to a known pathogenic variant (c.298+1G>A), as well as the novel autopsy finding of kernicterus with relatively low blood concentration of unconjugated bilirubin (UCB) (11.55 mg/dL). The patient was a full‐term male with a family history of two previous male siblings who died as newborns after acute neurologic deterioration. The patient's symptoms began at 24 h of life with lethargy that rapidly progressed to coma upon admission to the neonatal intensive care unit. Although hyperammonemia and hyperbilirubinemia were documented, hemofiltration could not be performed. OTCD diagnosis was biochemically established. Despite nutritional intervention and treatment for hyperammonemia, the patient died on the sixth day of life. At autopsy, external brain examination revealed a marked yellow pigmentation typical of kernicterus that included gray matter, particularly the thalamus and basal ganglia; dentate nuclei of the cerebellum and brain stem gray matter were also affected. Microscopic findings were consistent with the classical description of tissue damage in OTCD, including the presence of Alzheimer type II astrocytes in basal ganglia, necrosis, neuronal loss with spongiform degeneration and macrophage infiltration surrounded by astroglia. This condition may be an important comorbidity in newborns with hyperammonemia.
- 18 June 2014
- Published by Wiley in Clinical Genetics
- Vol. 88 (1) , 62-67
Phenylalanine hydroxylase deficiency in Mexico: genotype–phenotype correlations, BH4 responsiveness and evidence of a founder effect
The mutational spectrum of the phenylalanine hydroxylase gene (PAH) in Mexico is unknown, although it has been suggested that PKU variants could have a differential geographical distribution. Genotype–phenotype correlations and genotype‐based predictions of responsiveness to tetrahydrobiopterin (BH4) have never been performed. We sequenced the PAH gene and determined the geographic origin of each allele, mini‐haplotype associated, genotype–phenotype correlations and genotype‐based prediction of BH4 responsiveness in 48 Mexican patients. The mutational spectrum included 34 variants with c.60+5G>T being the most frequent (20.8%) and linked to haplotype 4.3 possibly because of a founder effect and/or genetic drift. Two new variants were found c.1A>T and c.969+6T>C. The genotype–phenotype correlation was concordant in 70.8%. The genotype‐based prediction to BH4‐responsiveness was 41.7%, this information could be useful for the rational selection of candidates for BH4 testing and therapy.
- 18 June 2014
- Published by Wiley in Clinical Genetics
- Vol. 88 (1) , 62-67
Phenylalanine hydroxylase deficiency in Mexico: genotype–phenotype correlations, BH4 responsiveness and evidence of a founder effect
The mutational spectrum of the phenylalanine hydroxylase gene (PAH) in Mexico is unknown, although it has been suggested that PKU variants could have a differential geographical distribution. Genotype–phenotype correlations and genotype‐based predictions of responsiveness to tetrahydrobiopterin (BH4) have never been performed. We sequenced the PAH gene and determined the geographic origin of each allele, mini‐haplotype associated, genotype–phenotype correlations and genotype‐based prediction of BH4 responsiveness in 48 Mexican patients. The mutational spectrum included 34 variants with c.60+5G>T being the most frequent (20.8%) and linked to haplotype 4.3 possibly because of a founder effect and/or genetic drift. Two new variants were found c.1A>T and c.969+6T>C. The genotype–phenotype correlation was concordant in 70.8%. The genotype‐based prediction to BH4‐responsiveness was 41.7%, this information could be useful for the rational selection of candidates for BH4 testing and therapy.
- 1 May 2014
- Published by Elsevier in Anales de Pediatría
- Vol. 80 (5) , 310-316
Caracterización de errores innatos del metabolismo intermediario en pacientes mexicanos
- 1 May 2014
- Published by Elsevier in Anales de Pediatría
- Vol. 80 (5) , 310-316
Caracterización de errores innatos del metabolismo intermediario en pacientes mexicanos
- Open Access
- 1 March 2014
- Published by Elsevier in Annals of Hepatology
- Vol. 13 (2) , 265-272
Tyrosinemia type I: clinical and biochemical analysis of patients in Mexico
- 1 March 2014
- Published by Elsevier in Annals of Hepatology
- Vol. 13 (2) , 265-272
Open AccessTyrosinemia type I: clinical and biochemical analysis of patients in Mexico
- 1 September 2012
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 19 (26) , 4511-4522
Tandem Mass Spectrometry Newborn Screening for Inborn Errors of Intermediary Metabolism: Abnormal Profile Interpretation
Expanded newborn screening for inherited metabolic disorders using tandem mass spectrometry was introduced in 1990’s and is widely used around the world. In contrast to conventional screening methods, tandem mass spectrometry does not measure single analytes but identifies and quantifies metabolite profiles; one single blood spot analyzed provides information of about 60 metabolites including amino acids, acylcarnitines and related ratios that enable the diagnosis of approximately 50 different diseases. However, the interpretation of these profiles can become quite complex. The aim of this work is to present in an easy and practical manner a comprehensive compilation of information needed for tandem mass neonatal screening profile interpretation, and basic actions for immediate follow up of abnormal results, including the tests that are required for confirmatory purposes. Other conditions not attributable to metabolic disorders which can lead to an abnormal profile of these markers are also described as well as a series of general recommendations which would be useful for health professionals who are beginning newborn screening for inborn errors of intermediary metabolism using tandem mass spectrometry.
- 1 September 2012
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 19 (26) , 4511-4522
Tandem Mass Spectrometry Newborn Screening for Inborn Errors of Intermediary Metabolism: Abnormal Profile Interpretation
Expanded newborn screening for inherited metabolic disorders using tandem mass spectrometry was introduced in 1990’s and is widely used around the world. In contrast to conventional screening methods, tandem mass spectrometry does not measure single analytes but identifies and quantifies metabolite profiles; one single blood spot analyzed provides information of about 60 metabolites including amino acids, acylcarnitines and related ratios that enable the diagnosis of approximately 50 different diseases. However, the interpretation of these profiles can become quite complex. The aim of this work is to present in an easy and practical manner a comprehensive compilation of information needed for tandem mass neonatal screening profile interpretation, and basic actions for immediate follow up of abnormal results, including the tests that are required for confirmatory purposes. Other conditions not attributable to metabolic disorders which can lead to an abnormal profile of these markers are also described as well as a series of general recommendations which would be useful for health professionals who are beginning newborn screening for inborn errors of intermediary metabolism using tandem mass spectrometry.
- 1 January 2012
- Published by Elsevier in Early Human Development
- Vol. 88 (1) , 61-64
Higher incidence of thyroid agenesis in Mexican newborns with congenital hypothyroidism associated with birth defects
- 1 January 2012
- Published by Elsevier in Early Human Development
- Vol. 88 (1) , 61-64
Higher incidence of thyroid agenesis in Mexican newborns with congenital hypothyroidism associated with birth defects
- Open Access
- 1 September 2011
- Published by SAGE Publications in Journal of Medical Screening
- Vol. 18 (3) , 115-120
Causes of delay in referral of patients with phenylketonuria to a specialized reference centre in Mexico
Objective: To expose causes leading to the delayed arrival of phenylketonuria (PKU) patients at a governmental reference centre (RC), and to describe their clinical characteristics. Material and methods: PKU files registered during the past 18 years at the National Institute of Pediatrics in Mexico City were evaluated. Patients were classified into two groups according to their age at arrival: Group I (early reference), patients arriving during the first month of life; and Group II (late reference), those who arrived after thirty days of age. Time and causes of delay were documented. Results: Of 57 recorded files, 10 were classified in Group I and 47 in Group II. Causes leading to the late arrival of Group II patients were absence of routine newborn screening (NBS), PKU not included in the routine NBS, sampling after the recommended age, false negative result, results without interpretation and/or instructions to follow, delayed notification of results, poor medical criteria of attending physician, difficulties in obtaining confirmatory tests, and administrative failures. Conclusion: The main cause of late referral of PKU patients was the absence of PKU testing. As a developing country, Mexico still faces challenges in the proper functioning and expansion of the NBS programme. Most PKU patients arrived at the RC late, presenting with varying degrees of the clinical spectrum. Incorporating PKU testing into the already established Mexican NBS system and adding quality indicators to guarantee proper operation in all NBS phases is necessary to achieve the goal of identifying, referring, diagnosing, and treating patients promptly.
- 1 September 2011
- Published by SAGE Publications in Journal of Medical Screening
- Vol. 18 (3) , 115-120
Open AccessCauses of delay in referral of patients with phenylketonuria to a specialized reference centre in Mexico
Objective: To expose causes leading to the delayed arrival of phenylketonuria (PKU) patients at a governmental reference centre (RC), and to describe their clinical characteristics. Material and methods: PKU files registered during the past 18 years at the National Institute of Pediatrics in Mexico City were evaluated. Patients were classified into two groups according to their age at arrival: Group I (early reference), patients arriving during the first month of life; and Group II (late reference), those who arrived after thirty days of age. Time and causes of delay were documented. Results: Of 57 recorded files, 10 were classified in Group I and 47 in Group II. Causes leading to the late arrival of Group II patients were absence of routine newborn screening (NBS), PKU not included in the routine NBS, sampling after the recommended age, false negative result, results without interpretation and/or instructions to follow, delayed notification of results, poor medical criteria of attending physician, difficulties in obtaining confirmatory tests, and administrative failures. Conclusion: The main cause of late referral of PKU patients was the absence of PKU testing. As a developing country, Mexico still faces challenges in the proper functioning and expansion of the NBS programme. Most PKU patients arrived at the RC late, presenting with varying degrees of the clinical spectrum. Incorporating PKU testing into the already established Mexican NBS system and adding quality indicators to guarantee proper operation in all NBS phases is necessary to achieve the goal of identifying, referring, diagnosing, and treating patients promptly.
- 31 January 2011
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 26 (2) , 260
Correspondence on ‘‘Experience With Hyperphenylalaninemia in a Developing Country: Unusual Clinical Manifestations and a Novel Gene Mutation’’
- 31 January 2011
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 26 (2) , 260
Correspondence on ‘‘Experience With Hyperphenylalaninemia in a Developing Country: Unusual Clinical Manifestations and a Novel Gene Mutation’’
- 1 March 2010
- Published by Elsevier in Clinical Biochemistry
- Vol. 43 (4-5) , 461-466
Clinical and biochemical characteristics of patients with urea cycle disorders in a developing country
- 1 March 2010
- Published by Elsevier in Clinical Biochemistry
- Vol. 43 (4-5) , 461-466
Clinical and biochemical characteristics of patients with urea cycle disorders in a developing country